Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2010
Business Stage: Development Stage Company
Operations: NanoViricides is a nano-biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for life-threatening viral infections (including HIV, Hepatitis, Influenza, Herpes, and Ebola). The company holds exclusive perpetual licenses from TheraCour Pharma, Inc. for its core technologies. As of the reporting date, the company has generated no revenues and has not commenced commercial product sales.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2010 | Six Months Ended Dec 31, 2009 | Cumulative (Inception to Dec 31, 2010) |
|---|---|---|---|
| Revenues | $0 | $0 | $0 |
| Net Loss | $(2,672,857) | $(1,656,637) | $(19,412,600) |
| Operating Expenses | $2,610,259 | $1,658,627 | $18,956,742 |
| Cash and Cash Equivalents (Ending) | $8,994,772 | $4,032,863 | $8,994,772 |
| Net Cash Used in Operating Activities | $(2,448,148) | $(711,877) | $(13,884,675) |
| Net Cash Provided by Financing Activities | $4,620,000 | $3,338,790 | $24,659,338 |
| Total Assets | $11,156,029 | N/A | N/A |
| Total Liabilities | $1,788,597 | N/A | N/A |
| Stockholders' Equity | $9,367,432 | N/A | N/A |
Note: The company reported a derivative liability of $460,246 as of December 31, 2010, related to Series B Convertible Preferred Stock.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended December 31, 2010, increased to $2.67 million from $1.66 million in the prior year period. This was driven primarily by a rise in Research and Development (R&D) expenses to $1.87 million (from $1.09 million) and General and Administrative expenses to $737,784 (from $564,902).
- Significant Financing Activity: The company raised approximately $4.62 million in net cash from financing activities during the six-month period, primarily through the issuance of Series B Convertible Preferred Stock to Seaside 88, LP. This contrasts with the prior year period where financing proceeds were lower.
- Cash Position: Cash and cash equivalents increased by approximately $2.04 million during the period, rising from $6.96 million at June 30, 2010, to $8.99 million at December 31, 2010.
- Derivative Liability Reduction: The derivative liability associated with convertible preferred stock decreased from $1,043,808 at June 30, 2010, to $460,246 at December 31, 2010, due to conversions and fair value adjustments.
Guidance, Outlook, and Risks
- Capital Requirements: Management estimates a need for an additional $10 million to $15 million over the next 18 months to fund toxicology studies, efficacy studies, and the preparation of an Investigational New Drug (IND) application for the FDA. The company currently has sufficient capital to operate for approximately 18 months at current expenditure rates.
- Development Pipeline: The company is advancing drug candidates for Influenza (FluCide-I), HIV (HIVCide-I), Herpes, Dengue, and Ebola/Marburg. Recent animal studies indicated that the Influenza candidate demonstrated significantly greater effectiveness than Tamiflu in lethal models.
- Risks and Contingencies:
- Going Concern: While the company currently has sufficient cash, it has incurred cumulative losses since inception and has no revenue. Continued losses are expected until commercialization.
- Financing Risk: There is no assurance that the company will be able to raise the additional capital required to complete its development plans.
- Regulatory Risk: The company has limited experience in pharmaceutical drug development, and budget estimates are based on consultant advice rather than historical experience.
- Related Party Transactions: The company relies heavily on TheraCour Pharma, Inc. (controlled by the company's President) for technology licensing and manufacturing, creating potential conflicts of interest and dependency risks.
Investor Verification Checklist
- Cash Burn Rate: Verify the accuracy of the 18-month runway estimate given the projected $10M-$15M funding gap.
- Related Party Dependencies: Review the terms of the license agreements with TheraCour Pharma, Inc., specifically regarding development fees and the 15% royalty on future net sales.
- Derivative Liability Valuation: Confirm the assumptions used to value the Series B Convertible Preferred Stock derivatives, as changes in stock price or volatility could materially impact reported losses.
- Regulatory Milestones: Monitor progress on the Toxicology Package and IND filing, as these are critical for transitioning from a development stage to a revenue-generating entity.
- Equity Dilution: Assess the impact of the automatic conversion features of the Series B Preferred Stock on existing common shareholders.